Conditions: Colorectal Cancer Metastases
Keywords: Colon, Rectal Cancer ABX-EGF, Panitumumab, EGFr Immunex, Abgenix, Amgen Metastatic Colorectal Cancer Vectibix
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 203
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.

Detailed description:

Arms:
arm 1: Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.

Interventions: intervention 1: Panitumumab
Intervention descriptions: intervention 1: Administered by intravenous infusion

Protocol document: